| Literature DB >> 26598693 |
Klaus Klumpp1, Angela M Lam2, Christine Lukacs3, Robert Vogel2, Suping Ren2, Christine Espiritu2, Ruth Baydo3, Kateri Atkins3, Jan Abendroth3, Guochun Liao4, Andrey Efimov5, George Hartman2, Osvaldo A Flores2.
Abstract
The hepatitis B virus (HBV) core protein is essential for HBV replication and an important target for antiviral drug discovery. We report the first, to our knowledge, high-resolution crystal structure of an antiviral compound bound to the HBV core protein. The compound NVR-010-001-E2 can induce assembly of the HBV core wild-type and Y132A mutant proteins and thermostabilize the proteins with a Tm increase of more than 10 °C. NVR-010-001-E2 binds at the dimer-dimer interface of the core proteins, forms a new interaction surface promoting protein-protein interaction, induces protein assembly, and increases stability. The impact of naturally occurring core protein mutations on antiviral activity correlates with NVR-010-001-E2 binding interactions determined by crystallography. The crystal structure provides understanding of a drug efficacy mechanism related to the induction and stabilization of protein-protein interactions and enables structure-guided design to improve antiviral potency and drug-like properties.Entities:
Keywords: HBV inhibitor; HBV treatment; capsid; core; protein–protein interaction
Mesh:
Substances:
Year: 2015 PMID: 26598693 PMCID: PMC4679053 DOI: 10.1073/pnas.1513803112
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205